Correlation between LincR-Gng2-5′and LincR-Epas1-3′as with the severity of multiple sclerosis in Egyptian patients

Shaker, Olfat G.; Golam, Rehab M.; Ayoub, Shymaa E.; Daker, Lamiaa I.; Elguaad, Mohamed K. Abd; Said, Eman S.; Khalil, Mahmoud A F

doi:10.1080/00207454.2019.1695610

Cited by 9 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, 33 studies were conducted in the Iranian population ( 24 – 26 , 28 – 34 , 36 , 38 – 43 , 45 – 55 , 57 , 58 , 61 , 66 , 67 ), 9 studies were in China ( 68 – 76 ), 5 studies were in Egypt ( 37 , 62 – 65 ), 4 studies were in Italy ( 27 , 35 , 59 , 60 ), 1 study was in Russia ( 44 ), and 1 study was in the Netherlands ( 56 ). A total of 44 studies evaluated the expression of lncRNAs in MS patients ( 24 , 26 – 31 , 34 – 43 , 45 , 46 , 48 , 50 – 54 , 56 – 61 , 63 – 65 , 67 – 76 ), while 9 other studies analyzed polymorphisms of lncRNAs ( 25 , 32 , 33 , 44 , 47 , 49 , 55 , 62 , 66 ). The details of the included studies are summarized in Tables 1 , 2 .…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Long Non-Coding RNAs, Novel Offenders or Guardians in Multiple Sclerosis: A Scoping Review

et al. 2021

View full text Add to dashboard Cite

Multiple sclerosis (MS), a chronic inflammatory demyelinating disease of the central nervous system, is one of the most common neurodegenerative diseases worldwide. MS results in serious neurological dysfunctions and disability. Disturbances in coding and non-coding genes are key components leading to neurodegeneration along with environmental factors. Long non-coding RNAs (lncRNAs) are long molecules in cells that take part in the regulation of gene expression. Several studies have confirmed the role of lncRNAs in neurodegenerative diseases such as MS. In the current study, we performed a systematic analysis of the role of lncRNAs in this disorder. In total, 53 studies were recognized as eligible for this systematic review. Of the listed lncRNAs, 52 lncRNAs were upregulated, 37 lncRNAs were downregulated, and 11 lncRNAs had no significant expression difference in MS patients compared with controls. We also summarized some of the mechanisms of lncRNA functions in MS. The emerging role of lncRNAs in neurodegenerative diseases suggests that their dysregulation could trigger neuronal death via still unexplored RNA-based regulatory mechanisms. Evaluation of their diagnostic significance and therapeutic potential could help in the design of novel treatments for MS.

show abstract

Section: Resultsmentioning

confidence: 99%

“…They are located in an important place rich in genes with immune regulatory functions. Since they act as enhancers, they might participate in the regulation of neighboring genes, thus modulating immune responses ( 63 ). LincR-Gng2-5′ is upregulated in MS patients, while LincR-Epas1-3′as is downregulated in these patients.…”

Section: Resultsmentioning

confidence: 99%

Long Non-Coding RNAs, Novel Offenders or Guardians in Multiple Sclerosis: A Scoping Review

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Fatty acids were quantified with the use of MultiQuant 2.1 software (AB Sciex, Foster City, CA, USA). Fold change (FC) >2 and p -value < 0.05 represent a significant result (Shaker et al, 2020 ). Metaboanalyst 3.0 ( http://www.metaboanalyst.ca ) was used for the metabolomic data analysis, interpretation, and visualization, which is presented as a heat map and a volcano plot (Xia et al, 2015 ).…”

Section: Methodsmentioning

confidence: 99%

Increased Epoxyeicosatrienoic Acids and Hydroxyeicosatetraenoic Acids After Treatment of Iodide Intake Adjustment and 1,25-Dihydroxy-Vitamin D3 Supplementation in High Iodide Intake–Induced Hypothyroid Offspring Rats

et al. 2021

View full text Add to dashboard Cite

Aim: This study aimed to investigate the potential role of fatty acids in high iodide intake–induced hypothyroidism and its complications and also in the intervention of iodide intake adjustment and 1,25-dihydroxy-vitamin D3 [1,25(OH)2D3] supplementation.Methods: Pregnant rats were allocated to two groups, namely, normal iodide (NI, 7.5 μg/day) intake and 100 times higher-than-normal iodide (100 HI, 750 μg/day) intake. The offspring were continuously administered potassium iodide from weaning [i.e., postnatal day 21 (PN21)] to PN90. After PN90, the offspring were either administered iodide intake adjustment (7.5 μg/day) or 1,25(OH)2D3 supplementation (5 μg·kg−1·day−1), or both, for 4 weeks. Thyroid function tests (free triiodothyronine, free thyroxine, thyrotropin, thyroid peroxidase antibody, and thyroglobulin antibody), blood lipids (triglyceride, total cholesterol, free fatty acid, and low-density lipoprotein cholesterol), and vitamin D3 (VD3) levels were detected by ELISA. Cardiac function was measured by echocardiography. Blood pressure was measured using a non-invasive tail-cuff system. The serum fatty acids profile was analyzed by liquid chromatography–mass spectrometry.Results: In the offspring rats with continued 100 HI administration, the levels of 8,9-dihydroxyeicosatrienoic acid (8,9-DHET) and thromboxane B2 (TXB2) were decreased, while those of prostaglandin J2 (PGJ2), prostaglandin B2 (PGB2), 4-hydroxydocosahexaenoic acid (4-HDoHE), 7-HDoHE, 8-HDoHE, and 20-HDoHE were increased. Significant correlations were found between PGB2, 8,9-DHET, 7-HDoHE levels and thyroid dysfunction, between PGJ2, 20-HDoHE, PGB2, 8,9-DHET levels and cardiac dysfunction, between PGJ2, 20-HDoHE levels and hypertension, between 4-HDoHE, 8-HDoHE, TXB2 levels and dyslipidemia, and between PGB2 and decreased VD3 level. After the treatment of iodide intake adjustment and 1,25(OH)2D3 supplementation, the levels of 16-hydroxyeicosatetraenoic acids (16-HETE), 18-HETE, 5,6-epoxyeicosatrienoic acid (5,6-EET), 8,9-EET, 11,12-EET, 14,15-EET, PGE2, 5-oxo-ETE, and 15-oxo-ETE were increased. The significant associations between PGE2, 16-HETE, 18-HETE and improved thyroid function and also between 5,6-EET, 11,12-EET, 14,15-EET, 16-HETE, 15-oxo-ETE and attenuated dyslipidemia were detected.Conclusion: Increased levels of prostaglandins (PGs) and HDoHEs and decreased levels of 8,9-DHET and TXB2 might occur in the progression of cardiac dysfunction, hypertension, and dyslipidemia in high iodide intake–induced hypothyroidism. The increased levels of EETs and HETEs might help to ameliorate these complications after iodide intake adjustment and 1,25(OH)2D3 supplementation.

show abstract

“…Several studies reported expression levels of lncRNAs in peripheral blood for their use as promising biomarkers of the disease; NEAT1, TUG1, PANDA [ 72 ], THRIL [ 73 ], lnc-DC [ 74 ], APOA1-AS, IFNG-AS1 [ 75 ], PINK1-AS [ 76 ], GAS8 and GAS8-AS1 [ 77 ] were upregulated in RRMS patients. In contrast, lincR-Gng2-5-AS [ 78 ] was upregulated in both RRMS and SPMS patients correlating to disease severity (EDSS) and showing excellent diagnostic power. NEAT1 expression was inversely correlated with age at onset and disease duration in female patients, while TUG1 was inversely correlated with disease duration in females [ 72 ].…”

Section: Long Non-coding Rnasmentioning

confidence: 99%

“…NEAT1 expression was inversely correlated with age at onset and disease duration in female patients, while TUG1 was inversely correlated with disease duration in females [ 72 ]. LincR-Epas1-3′AS was downregulated in peripheral blood of RRMS, and SPMS patients [ 78 ], PVT1, FAS-AS1 [ 73 ], lnc-MKI67IP, HNF1A-AS, LINC00305 [ 79 ], NR_003531.3 [ 80 ], SPRY-IT1, HOXA-AS2, LINC-ROR, and MEG3 [ 81 ] were significantly downregulated in peripheral blood of MS patients compared to controls with high diagnostic power. Table 3 , Table 4 summarize lncRNAs in MS used as biomarkers and their target proteins or pathways.…”

Section: Long Non-coding Rnasmentioning

confidence: 99%

Scavenging the hidden impacts of non-coding RNAs in multiple sclerosis

Elkhodiry

Tayebi

2021

Non-coding RNA Research

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic neuroinflammatory disease that causes severe neurological dysfunction leading to disabilities in patients. The prevalence of the disease has been increasing gradually worldwide, and the specific etiology behind the disease is not yet fully understood. Therapies aimed against treating MS patients have been growing lately, intending to delay the disease progression and increase the patients' quality of life. Various pathways play crucial roles in developing the disease, and several therapeutic approaches have been tackling those pathways. However, these strategies have shown several side effects and inconsistent efficacy. MicroRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs) have been shown to act as key players in various disease pathogenesis and development. Several proinflammatory and anti-inflammatory miRNAs have been reported to participate in the development of MS. Hence, the review assesses the role of miRNAs, lncRNAs, and circRNAs in regulating immune cell functions better to understand their impact on the molecular mechanics of MS.

show abstract

Correlation between LincR-Gng2-5′and LincR-Epas1-3′as with the severity of multiple sclerosis in Egyptian patients

Cited by 9 publications

References 30 publications

Long Non-Coding RNAs, Novel Offenders or Guardians in Multiple Sclerosis: A Scoping Review

Long Non-Coding RNAs, Novel Offenders or Guardians in Multiple Sclerosis: A Scoping Review

Increased Epoxyeicosatrienoic Acids and Hydroxyeicosatetraenoic Acids After Treatment of Iodide Intake Adjustment and 1,25-Dihydroxy-Vitamin D3 Supplementation in High Iodide Intake–Induced Hypothyroid Offspring Rats

Scavenging the hidden impacts of non-coding RNAs in multiple sclerosis

Contact Info

Product

Resources

About